main content start


Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Brightcove Cards Listing

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • nasopharyngeal carcinoma44m 35s

    Comprehensive Overview of Nasopharyngeal Carcinoma

    Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.
    nasopharyngeal carcinoma immunotherapy
  • Myelodysplastic Syndromes31m 24s

    Improving Diagnosis of MDS -Innovative Solutions

    Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
    mds diagnosis web based diagnosis her2negative mbc
  • Prostate Cancer11m 27s

    Management of Advanced Prostate Cancer: nmCRPC

    Recent advances in management of nmCRPC.
  • Multiple Myeloma6m 23s

    Bone Targeted Treatments in Multiple Myeloma 2024-03-VD-EM-MMY-07

    Long-term usage of bisphosphonates should be balanced with the potential of possible side-effects. Watch the detailed video on MedEnrich to learn about use of bone targeted agents, its dosage, frequency, optimal usage and limitations.
    bisphosphonates convenient agent bone lesions side-effects
  • OncoSpecials6m 24s

    2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients

    Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.
    2nd generation tki deep molecular response elts high risk e14a2 transcripts
  • Multiple Myeloma3m 12s

    Tips for Optimising Long Term Lenalidomide Maintenance in Multiple Myeloma

    Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.
    long term maintenance therapy lenalidomide tips
  • Breast Cancer8m 46s

    Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer

    Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
    anti-her2 directed therapy her2-positive metastatic breast cancer expert perspective algorithm for management of her2 positive mbc
  • Multiple Myeloma7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Myelodysplastic Syndromes2m 31s

    Duration of treatment does it improve outcomes Hypomethylating agents in MD

    Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
    duration of treatment hypomethylating agents mds
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing


    Webinar Cards Listing



    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback